IFN-γ-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1

Cancer Letters

Volumn 359, Issue 1, 2015, Pages 136-147

  Yuan, Li ^a   Zhou, Chang ^b   Lu, Yanxia ^a   Hong, Min ^a   Zhang, Zuoyang ^a   Zhang, Zheying ^a   Chang, Yaya ^a   Zhang, Chao ^a   Li, Xuenong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Colorectal cancer; IFN ; IRF1; Metastasis; MiR 29b

Indexed keywords

GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; MICRORNA 29B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; IGF1 PROTEIN, HUMAN; IRF1 PROTEIN, HUMAN; MICRORNA; MIRN29 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MICRORNA 29B GENE; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COLORECTAL NEOPLASMS; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; HT 29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME; TUMOR INVASION;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HT29 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922198345     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.003     Document Type: Article

References (40)

1. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
2. Ferrantini M., Capone I., Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007, 89:884-893.
3. Ni C., Wu P., Zhu X., Ye J., Zhang Z., Chen Z., et al. IFN-gamma selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells. Cancer Lett 2013, 336:174-184.
4. Gerber S.A., Sedlacek A.L., Cron K.R., Murphy S.P., Frelinger J.G., Lord E.M. IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am. J. Pathol 2013, 182:2345-2354.
5. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
6. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
7. Yang C.H., Yue J., Fan M., Pfeffer L.M. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010, 70:8108-8116.
8. Reinsbach S., Nazarov P.V., Philippidou D., Schmitt M., Wienecke-Baldacchino A., Muller A., et al. Dynamic regulation of microRNA expression following interferon-gamma-induced gene transcription. RNA Biol 2012, 9:978-989.
9. Matejuk A., Collet G., Nadim M., Grillon C., Kieda C. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. Arch. Immunol. Ther. Exp. (Warsz) 2013, 61:285-299.
10. Shenouda S.K., Alahari S.K. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev 2009, 28:369-378.
11. Lu Y.X., Yuan L., Xue X.L., Zhou M., Liu Y., Zhang C., et al. Regulation of colorectal carcinoma stemness, growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism. Clin. Cancer Res 2014, 20:2631-2642.
12. Wang R.T., Xu M., Song Z.G., Xu C.X., Jin H. Decreased expression of miR-216a contributes to non-small cell lung cancer progression. Clin. Cancer Res 2014, 10.1158/1078-0432.CCR-14-0517.
13. Wang Y., Zhang X., Li H., Yu J., Ren X. The role of miRNA-29 family in cancer. Eur. J. Cell Biol 2013, 92:123-128.
14. Fang J.H., Zhou H.C., Zeng C., Yang J., Liu Y., Huang X., et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011, 54:1729-1740.
15. Rothschild S.I., Tschan M.P., Federzoni E.A., Jaggi R., Fey M.F., Gugger M., et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 2012, 31:4221-4232.
16. Manceau G., Imbeaud S., Thiebaut R., Liebaert F., Fontaine K., Rousseau F., et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res 2014, 20:3338-3347.
17. Schmitt M.J., Margue C., Behrmann I., Kreis S. MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr. Mol. Med 2013, 13:572-585.
18. Schmitt M.J., Philippidou D., Reinsbach S.E., Margue C., Wienecke-Baldacchino A., Nashan D., et al. Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun. Signal 2012, 10:41.
19. Lee A.H., Hong J.H., Seo Y.S. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. Biochem. J. 2000, 350(Pt 1):131-138.
20. Ascierto M.L., De Giorgi V., Liu Q., Bedognetti D., Spivey T.L., Murtas D., et al. An immunologic portrait of cancer. J. Transl. Med 2011, 9:146.
21. Kim P.K., Armstrong M., Liu Y., Yan P., Bucher B., Zuckerbraun B.S., et al. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 2004, 23:1125-1135.
22. Yang W., Tan J., Liu R., Cui X., Ma Q., Geng Y., et al. Interferon-gamma upregulates expression of IFP35 gene in HeLa cells via interferon regulatory factor-1. PLoS ONE 2012, 7. e50932.
23. Wong H.L., Koh W.P., Probst-Hensch N.M., Van den Berg D., Yu M.C., Ingles S.A. Insulin-like growth factor-1 promoter polymorphisms and colorectal cancer: a functional genomics approach. Gut 2008, 57:1090-1096.
24. Zhou C., Liu G., Wang L., Lu Y., Yuan L., Zheng L., et al. MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1. PLoS ONE 2013, 8. e63142.
25. Yarilina A., Park-Min K.H., Antoniv T., Hu X., Ivashkiv L.B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol 2008, 9:378-387.
26. Kuo T.C., Calame K.L. B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J. Immunol 2004, 173:5556-5563.
27. Harada H., Fujita T., Miyamoto M., Kimura Y., Maruyama M., Furia A., et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989, 58:729-739.
28. Mott J.L., Kurita S., Cazanave S.C., Bronk S.F., Werneburg N.W., Fernandez-Zapico M.E. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J. Cell. Biochem 2010, 110:1155-1164.
29. Furstenberger G., Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol 2002, 3:298-302.
30. Key T.J., Appleby P.N., Reeves G.K., Roddam A.W. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010, 11:530-542.
31. Lukanova A., Lundin E., Toniolo P., Micheli A., Akhmedkhanov A., Rinaldi S., et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int. J. Cancer 2002, 101:549-554.
32. Chen W., Wang S., Tian T., Bai J., Hu Z., Xu Y., et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur. J. Hum. Genet 2009, 17:1668-1675.
33. Gao Y., Katki H., Graubard B., Pollak M., Martin M., Tao Y., et al. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int. J. Cancer 2012, 131:E105-E113.
34. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4:505-518.
35. Yong F.L., Law C.W., Wang C.W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 2013, 13:280.
36. Krok K.L., Lichtenstein G.R. Colorectal cancer in inflammatory bowel disease. Curr. Opin. Gastroenterol 2004, 20:43-48.
37. Murtas D., Maric D., De Giorgi V., Reinboth J., Worschech A., Fetsch P., et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br. J. Cancer 2013, 109:76-82.
38. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
39. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
40. Maki R.G. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol 2010, 28:4985-4995.